Videira PAQ, Castro-Caldas M. Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson’s disease. Front Neurosci. 2018;12:381.
Kulisevsky J, Oliveira L, Fox SH. Update in therapeutic strategies for Parkinson’s disease. Curr Opin Neurol. 2018;31(4):439–47.
Ko EJ, Chae M, Cho SR. Relationship between swallowing function and maximum phonation time in patients with Parkinsonism. Ann Rehabil Med. 2018;42(3):425–32.
Plowman-Prine EK, Sapienza CM, Okun MS, Pollock SL, Jacobson C, Wu SS, et al. The relationship between quality of life and swallowing in Parkinson’s disease. Mov Disord. 2009;24(9):1352–8.
van Hooren MR, Baijens LW, Voskuilen S, Oosterloo M, Kremer B. Treatment effects for dysphagia in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2014;20(8):800–7.
van Hooren MR, Baijens LW, Vos R, Pilz W, Kuijpers LM, Kremer B, et al. Voice- and swallow-related quality of life in idiopathic Parkinson’s disease. Laryngoscope. 2016;126(2):408–14.
Tomita S, Oeda T, Umemura A, Kohsaka M, Park K, Yamamoto K, et al. Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson’s disease. PLoS One. 2015;10(8):e0136722.
Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson’s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. BMJ Open. 2018;8(2):e018969.
Mantri S, Fullard ME, Beck J, Willis AW. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. NPJ Parkinsons Dis. 2019;5(1) https://doi.org/10.1038/s41531-019-0074-8.
Dorsey ER, Sherer T, Okum MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Park Dis. 2018;8(s1):S3–8.
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Park Dis. 2017;7(s1):S71–85.
Mori F, Tanji K, Zhang H, Kakita A, Takahashi H. Wakabayashi K. alpha-synuclein pathology in the neostriatum in Parkinson’s disease. Acta Neuropathol. 2008;115(4):453–9.
Zhang QS, Heng Y, Yan YH, Chen NH. Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Toxicol Lett. 2017;265:30–7.
Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflammation. 2006;3:6.
Leopold N, Kagel M. Pharyngoesophageal dysphagia in Parkinson’s disease. Dysphagia. 1997;12(1):11–8; discussion 19–20
Warnecke T, Suttrupa I, Schroder JB, Osadab N, Oelenberg S, Hamachera C, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES levodopa test. Parkinsonism Relat Disord. 2016;28:100–6.
Warnecke T, Oelenberg S, Teismann I, Hamacher C, Lohmann H, Ringelstein EB, Dziewas R. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord. 2010;25(9):1239–45.
Reichmann H. Clinical criteria for the diagnosis of Parkinson’s disease. Neurodegener Dis. 2010;7(5):284–90.
Brooks DJ. Parkinson’s disease: diagnosis. Parkinsonism Relat Disord. 2012;18(Suppl 1):S31–3.
Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson’s disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018;89(12):1288–95.
Novakovic D, MacKay S. Adult obstructive sleep apnoea and the larynx. Curr Opin Otolaryngol Head Neck Surg. 2015;23(6):464–9.
Dedhia RC, Rosen CA, Soose RJ. What is the role of the larynx in adult obstructive sleep apnea? Laryngoscope. 2014;124(4):1029–34.
Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson’s disase and other parkinsonisms. Funct Neurol. 2017;32(3):137–41.
Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O’Connell D, Senat JM, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol. 1999;22(4):213–5.
Sato H, Yamamoto T, Sato FY, Murata M. Dysphagia causes symptom fluctuations after oral L-dopa treatment in a patient with Parkinson disease. Case Rep Neurol. 2018;10(1):101–7.
Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, et al. α-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson’s disease. J Neuropathol Exp Neurol. 2013;72(2):119–29.
Miles A, Jardine M, Johnston F, de Lisle M, Friary P, Allen J. Effect of Lee Silverman Voice Treatment (LSVT®) on swallowing and cough function in people with Parkinson’s disease. J Neurol Sci. 2017;383:180–7.
Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31(1):24–32.
Suttrup I, Suttrup J, Suntrup-Krueger S, Siemer ML, Bauer J, Hamacher C, et al. Esophageal dysfunction in different stages of Parkinson’s disease. Neurogastroenterol Motil 2017. https://doi.org/10.1111/nmo.12915. Epub ahead of print.
Derrey S, Chastan N, Maltete D, Verin E, Dechelotte P, Lefaucheur R, et al. Impact of deep brain stimulation on pharyngo-esophageal motility: a randomized cross-over study. Neurogastroenterol Motil. 2015;27(9):1214–22.
Sung HY, Kim JS, Lee KS, Kim YI, Song IU, Chung SW, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov Disord. 2010;25(14):2361–8.
El-Sharkawi A, Ramig L, Logemann JA, Pauloski BR, Rademaker AW, Smith CH, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002;72(1):31–6.
Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias. Eur J Neurol. 2009;16(8):895–901.
Sheard JM, Ash S, Silburn PA, Kerr GK. Prevalence of malnutrition in Parkinson’s disease: a systematic review. Nutr Rev. 2011;69(9):520–32.
Plowman-Prine EK, Okun MS, Sapienza CM, Shrivastav R, Fernandez HH, Foote KD, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. Neuropsychol Rehabil. 2009;24(2):131–44.
Moon S, Schmidt M, Smirnova IV, Colgrove Y, Liu W. Qigong exercise may reduce serum TNF-α levels and improve sleep in people with Parkinson’s disease: a pilot study. Medicines (Basel). 2017;4(2) https://doi.org/10.3390/medicines4020023.
Park A, Zid D, Russell J, Malone A, Rendon A, Wehr A, Li X. Effects of a formal exercise program on Parkinson’s disease: a pilot study using a delayed start design. Parkinsonism Relat Disord. 2014;20(1):106–11.
Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson’s disease and other neurological disorders. Semin Speech Lang. 2006;27(4):283–99.
Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment for voice, speech and other orofacial disorders in patients with Parkinson’s disease. Future Neurol. 2006;1:563–70.
Sapir S, Spielman JL, Ramig LO, Story BH, Fox C. Effects of intensive voice treatment the Lee Silverman Voice Treatment (LSVT) on vowel articulation in dysarthric individuals with idiopathic Parkinson’s disease: acoustic and perceptual findings. J Speech Lang Hear Res. 2007;50(4):899–912.
Pitts T, Bolser D, Rosenbek J, Troche M, Okun M, Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest. 2009;135(5):1301–8.
Johnson DN, Herring HJ, Daniels SK. Dysphagia management in stroke rehabilitation. Curr Phys Med Rehabil Rep. 2014;2(4):207–18.
Athukorala RP, Jones RD, Sella O, Huckabee ML. Skill training for swallowing rehabilitation in patients with Parkinson’s disease. Arch Phys Med Rehabil. 2014;95(7):1374–82.
Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology. 2010;75(21):1912–9.
Park JS, Oh DH, Hwang NK, Lee JH. Effects of neuromuscular electrical stimulation in patients with Parkinson’s disease and dysphagia: a randomized, single-blind placebo-controlled trial. NeuroRehabilitation. 2018;42(4):457–63.
Troche MS, Rosenbek JC, Okun MS, Sapienza CM. Detraining outcomes with expiratory muscle strength training in Parkinson’s disease. J Rehabil Res Dev. 2014;51(2):305–10.
Ludlow CL. Electrical neuromuscular stimulation in dysphagia: current status. Curr Opin Otolaryngol Head Neck Surg. 2010;18(3):159–64.
Russell JA, Ciucci MR, Connor NP, Schallert T. Targeted exercise therapy for voice and swallow in persons with Parkinson’s disease. Brain Res. 2010;1341:3–11.
Sapir S, Ramig LO, Fox CM. Intensive voice treatment in Parkinson’s disease: Lee Silverman voice treatment. Expert Rev Neurother. 2011;11(6):815–30.
Ramig LO, Sapir S, Fox C. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson’s disease: a comparison with untreated peoples and normal age-matched controls. Mov Disord. 2001;16(1):79–83.
Ramig LO, Sapir S, Countryman S, Pawlas AA, O’Brien C, Hoehn M, Thompson LL. Intensive voice treatment (LSVT) for peoples with Parkinson's disease: a 2-year follow up. J Neurosurg Psychol. 2001;71(4):493–8.
Ramig LO, Fox C, Sapir S. Parkinson’s disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. Semin Speech Lang. 2004;25(2):169–80.
Constantinescu G, Theodoros D, Russell T, Ward E, Wilson S, Wootton R. Treating disordered speech and voice in Parkinson’s disease online: a randomized controlled non-inferiority trial. Int J Lang Commun Disord. 2011;46(1):1–16.
Manor Y, Posen J, Amir O, Dori N, Giladi N. A group intervention model for speech and communication skills in patients with Parkinson’s disease initial observations. Comm Dis Quart. 2005;26(2):94–101.
Plourde JMH, Purdy SC, Moore C, Friary P, Brown R, McCann C. Gavel Club for people with aphasia: communication confidence and quality of communication life. Aphasiology. 2019;33(1):73–93.
Fogg-Rogers L, Buetow S, Talmage A, McCann C, Leão SHS, Tippett L, et al. Choral singing therapy following stroke or Parkinson’s disease: an exploration of participants’ experiences. Disabil Rehabil. 2016;38(10):952–62.
Seagall LE. The effect of group singing on the voice and swallow function of healthy, sedentary, older adults: a pilot study. Arts Psychother. 2017;55:40–5.
Stegemoller EL, Radig H, Hibbing P, Wingate J, Sapienza C. Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease. Disabil Rehabil. 2017;39(6):594–600.
Di Benedetto P, Cavazzon M, Mondolo F, Rugiu G, Peratoner A, Biasutti E. Voice and choral singing treatment: a new approach for speech and voice disorders in Parkinson’s disease. Eur J Phys Rehabil Med. 2009;45(1):13–9.
Han EY, Yn JY, Chong HJ, Choi KG. Individual therapeutic singing program for vocal quality and depression in Parkinson’s disease. J Mov Disord. 2018;11(3):121–8.
Stegemoller EL, Hibbing P, Radig H, Wingate J. Therapeutic singing as an early intervention for swallowing in persons with Parkinson’s disease. Complement Ther Med. 2017;31:127–33.
Elefant C, Baker FA, Lota M, Lagesen SK, Skeie GO. The effect of group music therapy on mood, speech, and singing in individuals with Parkinson’s disease – a feasibility study. J Music Ther. 2012;49(3):278–302.
Mathew D, Sundar S, Subramaniam E, Parmar PN. Music therapy as a group singing improves Geriatric Depression Scale score and loneliness in institutionalised geriatric adults with mild depression: a randomised controlled study. Int J Educ Psychol Res. 2017;3(1):6–10.
Talmage A, Ludlam S, Leão S, Fogg-Rogers LA, Purdy SC. Leading the celebration choir: the choral singing therapy protocol and the role of the music therapist in a social singing group for adults with neurological conditions. NZ. J Music Ther. 2013;11:7–50.
Annus A, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:143–51.
Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag. 2018;8(2):73–80.
Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep. 2005;57(6):701–12.
Ogawa T, Oyama G, Hattori N. Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation. BMJ Case Rep. 2018; https://doi.org/10.1136/bcr-2017-223722.
Dafotakis M, Sparing R, Juzek A, Block F, Kosinski CM. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci. 2009;16(2):335–7.
Hattori N, Hasegawa K, Sato K, Mitsuyama E, Numachi Y. Clinical evaluation of ropinirole controlled-release formulation at 18-24mg/day in Japanese patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;40:33–9.
Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, et al. A randomized trial of low-dose Rasagiline and pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017;32(5):783–9.
Cansino-Torres MA, Sandoval-Rodríguez V, Sáenz-Farrett M, Zúñiga-Ramírez C. Allergy to carbidopa. Clin Neuropharmacol. 2018;41(2):75–9.
de Rus Jacquet A, Timmers M, Ma SY, Thieme A, McCabe GP, Vest JHC, et al. Lumbee traditional medicine: neuroprotective activities of medicinal plants used to treat Parkinson’s disease-related symptoms. J Ethnopharmacol. 2017;206:408–25.
Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S11–3.
Oad MA, Miles A, Lee A, Lambie A. Medicine administration in people with Parkinson’s disease in New Zealand: an interprofessional, stakeholder-driven online survey. Dysphagia. 2019;34(1):119–28.
Patel K. Optimising medication for Parkinson’s disease patients with dysphagia. Br J Community Nurs. 2015;20(7):322–6.
Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR. Medication therapy management service for patients with Parkinson’s disease: a before-and-after study. Neurol Ther. 2016;5(1):85–99.
Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:33–7.
Tate P, Pandey S. Botulinum toxin in movement disorders. Neurol India. 2018;66(Suppl 1):79–89.
Born LJ, Hamed RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord. 1996;11(1):53–8.
Olchik MR, Ghisi M, Ayres A, Schuh AFS, Oppitz PP, de Mello Rieder CR. The impact of deep brain stimulation on the quality of life and swallowing in individuals with Parkinson’s disease. Int Arch Otorhinolaryngol. 2018;22(2):125–9.
Xie T, Bloom L, Padmanaban M, Bertacchi B, Kang W, MacCracken E, et al. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018;89(9):989–94.